Dova Pharmacuet (NASDAQ:DOVA) CEO Alex Sapir acquired 20,100 shares of the stock in a transaction dated Wednesday, July 5th. The stock was acquired at an average price of $17.00 per share, with a total value of $341,700.00. Following the completion of the acquisition, the chief executive officer now owns 20,100 shares in the company, valued at approximately $341,700. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of Dova Pharmacuet (NASDAQ DOVA) traded up 9.14% during midday trading on Monday, hitting $27.47. 186,295 shares of the stock were exchanged. The company’s market capitalization is $686.48 million. Dova Pharmacuet has a 52-week low of $18.18 and a 52-week high of $28.59.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by WKRB News and is the property of of WKRB News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.wkrb13.com/markets/2286351/dova-pharmacuet-nasdaqdova-ceo-alex-sapir-purchases-20100-shares.html.
Dova Pharmacuet Company Profile
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2286351/dova-pharmacuet-nasdaqdova-ceo-alex-sapir-purchases-20100-shares.html
Receive News & Ratings for Dova Pharmacuet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmacuet and related companies with MarketBeat.com's FREE daily email newsletter.